BRKRNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BRKRP
BRUKER CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$55.37+0.57 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $8.43B
- P/E (TTM)
- –
- Dividend yield
- –
BRUKER CORP revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSI CALID | $1.21B | $1.09B | $960.40M | $822.20M | $819.60M | $653.90M | – | – | – | – | 35.2% | +10.7% |
| BSI NANO | $1.08B | $1.10B | $941.90M | $787.00M | $697.50M | $556.10M | $632.70M | $568.10M | – | – | 31.6% | -1.3% |
| BSI BioSpin | $878.80M | $905.70M | $798.50M | $696.70M | $691.00M | $600.00M | – | – | – | – | 25.6% | -3.0% |
| BEST | $270.90M | $283.00M | $280.70M | $237.10M | $223.80M | $189.50M | $209.90M | $194.80M | $191.20M | $130.20M | 7.9% | -4.3% |
| BSI Life Science | – | – | – | – | $1.51B | $1.25B | $1.24B | $1.14B | $1.07B | $1.49B | – | – |
| BSI Material Science | – | – | – | – | – | – | $632.70M | $568.10M | $513.00M | – | – | – |
| BSI BioSpin | – | – | – | – | $691.00M | $600.00M | $621.40M | $591.10M | – | – | – | – |
| Bruker NANO | – | – | – | – | $697.50M | $556.10M | $632.70M | $568.10M | – | – | – | – |
| Bruker CALID | – | – | – | – | $819.60M | $653.90M | $623.50M | $547.80M | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unallocated Expenses | $364.80M | $264.90M | $109.40M | $72.90M | – | – | – | – | – | – | +37.7% |
| BSI CALID | $262.60M | $246.20M | $232.10M | $216.40M | $227.20M | $152.20M | – | – | – | – | +6.7% |
| BSI BioSpin | $156.50M | $216.60M | $211.20M | $187.70M | $158.20M | $121.60M | – | – | – | – | -27.7% |
| BSI NANO | $101.10M | $123.90M | $158.40M | $138.10M | $73.40M | $23.60M | $40.40M | $48.40M | – | – | -18.4% |
| BEST | $26.70M | $35.10M | $32.50M | $30.40M | $22.20M | $6.20M | $16.40M | $14.50M | $7.40M | $6.60M | -23.9% |
| BSI Life Science | – | – | – | – | $385.40M | $273.80M | $290.30M | $244.00M | $212.20M | $173.50M | – |
| BSI Material Science | – | – | – | – | – | – | $40.40M | $48.40M | $24.30M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $2.77B | $2.76B | $2.46B | $2.11B | $2.02B | $1.64B | $1.74B | $1.58B | $1.48B | $1.35B | 80.5% | +0.3% |
| Service and other revenue | $670.10M | $607.20M | $506.90M | $420.80M | $7.40M | $6.00M | $5.50M | $7.30M | $8.20M | $11.20M | 19.5% | +10.4% |
| Service | – | – | $493.80M | $414.60M | $393.20M | $343.40M | $322.40M | $311.70M | $278.20M | $254.70M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe excluding Germany | $950.20M | $873.00M | $699.70M | – | – | – | – | – | – | – | 27.7% | +8.8% |
| United States | $891.30M | $938.50M | $777.70M | $696.10M | $601.00M | $455.90M | $529.80M | $489.40M | $434.70M | $428.20M | 25.9% | -5.0% |
| Asia Pacific excluding China | $552.60M | $518.50M | $460.90M | – | – | – | – | – | – | – | 16.1% | +6.6% |
| China | $475.80M | $471.20M | $528.10M | $396.50M | $357.60M | $313.50M | – | – | – | – | 13.8% | +1.0% |
| Germany | $297.00M | $310.70M | $281.50M | $247.40M | $262.60M | $244.90M | $213.60M | $201.10M | $200.20M | $189.50M | 8.6% | -4.4% |
| Other | $269.60M | $254.50M | $216.60M | $190.40M | $167.10M | $137.80M | $173.00M | $155.70M | $151.20M | $142.10M | 7.8% | +5.9% |
| Rest of Europe | – | $873.00M | $699.70M | $591.90M | $658.10M | $519.80M | $505.20M | $500.20M | $465.00M | $393.40M | – | – |
| Asia Pacific | – | – | $460.90M | $408.40M | $371.50M | $315.60M | $651.00M | $549.20M | $514.80M | $458.10M | – | – |
| Rest of Asia Pacific | – | $518.50M | $460.90M | $408.40M | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Bruker's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.